IHVR-19029

IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC₅₀ of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy^[1][2][3][4]. In Vitro: IHVR-19029 efficiently inhibits Bovine viral diarrhea virus (BVDV), Tacaribe virus (TCRV) and Dengue virus (DENV) with EC₅₀s of 0.25, 0.74, and 1.25 μM, respectively^[2]. The combination of IHVR-19029 and Favipiravir (HY-14768) synergistically inhibits the replication of Yellow fever and Ebola viruses in cultured cells^[4]. In Vivo: IHVR-19029 (25-75 mg/kg; I.p.; twice daily for 10 days) inhibits EBOV and MARV infection in mice^[2].
IHVR-19029 (5 mg/kg; i.v.) has AUC, C₀, T_1/2, CL and V_d values of 1383 μg*h/mL, 1.79 μg/mL, 1.2 hours, 3.49 L/h/kg, and 3.0 L/kg, respectively^[2].
IHVR-19029 (75/5/5 mg/kg; p.o./i.m./i.p.) has AUC values of 945/1839/983 μg*h/mL, C_max values of 0.26/1.23/1.33 μg/ml, T_max values of 2.1/0.1/0.17 hours, and F values of 4.6/71/133%, respectively^[2].